Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme CEO Henri A. Termeer On Big Pharma’s Transformation To Becoming Leaner Machines: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Genzyme CEO Henri A. Termeer, has seen his company grow from a small entrepreneurial venture into one of the world's largest biotech companies. Having held several prestigious positions like deputy chairman of the Federal Reserve Bank of Boston's board of directors and chairman of the board of Medical Simulation Corp, Termeer is recognized globally for his contributions in the field of biotechnology. With a growth record of 20 percent annually for the past five years, Termeer is now looking beyond American shores to keep with the growth momentum. In an interview with PharmAsia News' India bureau during a World Economic Forum meeting in New Delhi, Termeer speaks on the challenges of the global pharmaceutical industry and the role of emerging markets like India and China.

You may also be interested in...



In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal

MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors

In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal

MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors

Genzyme CEO Henri A. Termeer On Big Pharma’s Transformation To Becoming Leaner Machines: An Interview With PharmAsia News (Part 1 of 2)

Genzyme CEO Henri A. Termeer has seen his company grow from a small entrepreneurial venture into one of the world's largest biotech companies. Having held several prestigious positions like deputy chairman of the Federal Reserve Bank of Boston's board of directors and chairman of the board of Medical Simulation Corp, Termeer is recognized globally for his contributions in the field of biotechnology. With a growth record of 20 percent annually for the past five years, Termeer is now looking beyond American shores to keep with the growth momentum. In an interview with PharmAsia News' India bureau during a World Economic Forum meeting in New Delhi, Termeer speaks on the challenges of the global pharmaceutical industry and the role of emerging markets like India and China.

Latest News
See All
UsernamePublicRestriction

Register

SC067419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel